VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation.
The expanded program builds on the success of the first batch of AI-designed PARP1-selective inhibitors announced earlier this year. These new compounds are being tailored to optimize efficacy, safety, and pharmacokinetic profiles, targeting critical unmet needs in oncology, including central nervous system (CNS) malignancies.
Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR.
AI-derived drug candidates are first validated in silico before being synthesized and evaluated for in vitro and in vivo activity against a specific target product profile in the Company’s laboratories at the University of British Columbia. Rakovina Therapeutics plans to advance the most promising lead candidates into human clinical trials in collaboration with pharmaceutical industry partners.
Leveraging AI for Revolutionary Advances in Cancer Treatment
The potential of artificial intelligence to accelerate medical breakthroughs has never been more apparent. Recent comments from leaders in AI and healthcare highlight the transformative role this technology will play in curing diseases at an unprecedented pace. Sam Altman, CEO of OpenAI, recently stated, “We will see diseases get cured at an unprecedented rate. We will be amazed at how quickly we’re curing this cancer and that one — and heart disease. AI will cure the diseases at a rapid, rapid rate.”
Similarly, Oracle CEO Larry Ellison emphasized AI’s ability to revolutionize early cancer detection and personalized treatments, stating, “If you can do it using AI, you can do early cancer detection with a blood test... Once we gene sequence that cancer tumor, you can then vaccinate the person — design a vaccine for every individual person... in about 48 hours.”
These bold predictions align with Rakovina’s approach to combine cutting-edge AI with world-class scientific expertise. By leveraging AI platforms like Deep Docking™ and Enki™, Rakovina Therapeutics is poised to contribute to this new era of rapid medical advancements, accelerating the development of innovative cancer therapies.
Advancing Innovation and Expanding Potential
Each set of compounds is being developed to address specific therapeutic gaps, including the treatment of cancers that involve the brain, such as BRCA-mutated metastatic breast cancer and glioblastoma. Leveraging its collaborations for utilizing the Deep Docking and Enki systems, Rakovina continues to employ cutting-edge artificial intelligence to accelerate drug discovery and bring meaningful therapies closer to patients in need.
“This expansion demonstrates the scalability and impact of our AI platform partnership,” said Prof. Mads Daugaard, Chief Scientific Officer. “With additional compounds in the pipeline, we are dramatically increasing the potential for identifying novel therapeutics to tackle some of the most challenging cancers. This ongoing development exemplifies our commitment to innovation and efficiency in cancer research.”
Jeffrey Bacha, Executive Chairman, added, “The addition of these AI-designed compounds significantly broadens our pipeline potential and will accelerate progress toward delivering life-changing treatments. By rapidly scaling our efforts, we are addressing the growing demand for innovative cancer therapies with unprecedented precision and speed.”
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.
For Further Information Contact: Michelle Seltenrich, BSc MBA Director, Corporate Development IR@rakovinatherapeutics.com 778-773-5432
